P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells
David Chiron,David Chiron,David Chiron,Sophie Maïga,Sophie Maïga,Sophie Maïga,Sylvanie Surget,Sylvanie Surget,Sylvanie Surget,Géraldine Descamps,Géraldine Descamps,Géraldine Descamps,Patricia Gomez-Bougie,S Traore,Nelly Robillard,Philippe Moreau,S. Le Gouill,Régis Bataille,Régis Bataille,Martine Amiot,Martine Amiot,Martine Amiot,Catherine Pellat-Deceunynck +22 more
TL;DR: The autocrine role of IGF1 in myeloma cells is highlighted and the interest in targeting IGF1R in IGFR1+ CD45+/− patients, such as MMSET+ patients, is reinforced.
Journal ArticleDOI
Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other
Sylvanie Surget,Emilie Lemieux-Blanchard,Sophie Maïga,Géraldine Descamps,Steven Le Gouill,Philippe Moreau,Martine Amiot,Catherine Pellat-Deceunynck +7 more
TL;DR: The combined effect of BDM andMelphalan was additive, and that BDM did not overcome melphalan resistance and vice versa, and it was demonstrated that the combined effect was additive.
Journal ArticleDOI
Report of the 6th International Workshop on PET in lymphoma
Cristina Nanni,Anne-Ségolène Cottereau,Egesta Lopci,Caroline Bodet-Milin,Mónica Coronado,Barbara Pro,Wong Seog Kim,Judith Trotman,Sally F. Barrington,Ulrich Dührsen,Thierry Vander Borght,Elena Zamagni,Françoise Kraeber-Bodéré,Christina Messiou,Alain Rahmouni,Irène Buvat,Marc André,Mark P. Hertzberg,Wim J.G. Oyen,Olivier Casasnovas,Stefano Luminari,Laurent Garderet,Françoise Montravers,Carsten Kobe,Regine Kluge,Annibale Versari,Emanuele Zucca,Philippe Moreau,Bruce D. Cheson,Corinne Haioun,Andrea Gallamini,Michel Meignan +31 more
TL;DR: The aim was to establish from the experience of Italian and French studies new guidelines of FDG-PET/CT reporting for myeloma staging and restaging, and the potential role of baseline metabolic tumor measurement to predict outcome and identify different risk categories was presented.
Journal ArticleDOI
A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma
TL;DR: A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma.
Book ChapterDOI
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
TL;DR: High dose therapy with autologous stem cell transplantation (ASCT) is the standard of care for eligible newly diagnosed MM patients, and recent data suggest that the upfront combination of a proteasome inhibitor plus one immunomodulatory drug (IMiD) is highly effective.